Dynavax up as FDA agrees to expanded Heplisav indication

Dynavax Technologies Corp. (NASDAQ:DVAX) gained $0.40 (11%) to 4.06 on Thursday after agreeing with FDA to expand the age range of the proposed indication for the company's Heplisav HBV vaccine. Dynav...